8-K: TELA Bio Appoints Industry Veteran Jeffrey Blizard as President, Strengthening Executive Leadership

TELA Bio, Inc. announced the appointment of Jeffrey Blizard, a former board member and experienced medical device executive, as its new President, effective June 2, 2025.

Summary

• TELA Bio, Inc. has appointed Jeffrey Blizard as its new President, effective June 2, 2025.
• Mr. Blizard previously served on TELA Bio's Board of Directors since June 2024 and resigned from the Board and the Nominating and Corporate Governance Committee, effective June 2, 2025, a decision not stemming from any disagreement with the company.
• Antony Koblish will continue as Chief Executive Officer but will no longer hold the title of President.
• Mr. Blizard, 56, brings extensive experience from his role as Global Head of Surgical Sales at Abiomed (a Johnson & Johnson company) and senior sales leadership positions at Medtronic, HeartWare, Intuitive Surgical, and Boston Scientific.
• His compensation package includes an annual base salary of $475,000, a target annual bonus opportunity of 50% of his base salary (pro-rated for 2025), and a $150,000 cash sign-on bonus.
• Equity awards granted to Mr. Blizard include an option to purchase 154,100 shares of common stock (vesting 25% on the first anniversary, then monthly over 36 months) and 104,800 restricted stock units (vesting in four equal annual installments starting on the first anniversary).
• The employment agreement outlines severance benefits if Mr. Blizard is terminated without Cause or resigns for Good Reason, including nine months of base salary and health benefits, or 12 months and accelerated equity vesting during a change of control period.

Sentiment

Score: 8

Explanation: The appointment of a highly experienced and respected industry veteran to a key executive role, coupled with positive management commentary about future growth and commercial performance, indicates a strong positive sentiment. The compensation package is standard for such a role and reflects the value placed on his expertise.

Positives

• The appointment of Jeffrey Blizard as President is expected to strengthen TELA Bio's executive leadership team, leveraging his deep industry experience and proven track record in scaling businesses.
• Mr. Blizard's background as Global Head of Surgical Sales at Abiomed, where he substantially grew the Surgical Division, suggests strong commercial leadership capabilities.
• His extensive experience with leading medtech companies like Medtronic, Intuitive Surgical, and Boston Scientific is anticipated to drive meaningful commercial performance and deepen customer relationships.
• The company views this leadership evolution as an 'important inflection point' for its next phase of growth trajectory.

Risks

• The press release contains forward-looking statements that are not guarantees of future performance and are subject to certain risks, uncertainties, and other factors that could cause actual results to differ materially and adversely.
• These general risks and uncertainties are described more fully in the 'Risk Factors' section of the company's filings with the SEC, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Future Outlook

TELA Bio anticipates that the appointment of Jeffrey Blizard will amplify its ability to compete and succeed in the dynamic medical technology market, driving meaningful commercial performance and reinforcing its commitment to delivering exceptional value to stakeholders as it moves into its next phase of growth.

Management Comments

• Antony Koblish, Co-Founder and Chief Executive Officer of TELA Bio, stated: "This is an important inflection point for TELA Bio. As we move into the next phase of our growth trajectory, we believe the addition of Jeff—a highly respected leader with a track record of scaling businesses and inspiring teams—will amplify our ability to compete and win in a dynamic market. We are confident that this leadership evolution will drive meaningful commercial performance and reinforce our commitment to delivering exceptional value to our customers, partners, and shareholders."
• Jeffrey Blizard, newly appointed President of TELA Bio, commented: "TELA Bio has built an extraordinary foundation and a differentiated portfolio that is redefining soft tissue reconstruction. I’m thrilled to join a mission-driven team with such momentum and look forward to working alongside our talented leadership and commercial teams to accelerate execution, deepen customer relationships, and scale our impact."

Industry Context

The appointment of a seasoned executive from major medical device companies like Johnson & Johnson's Abiomed, Medtronic, Intuitive Surgical, and Boston Scientific suggests TELA Bio is strategically enhancing its commercial capabilities to gain market share in the competitive soft-tissue reconstruction sector. This move aligns with a trend of medical technology companies seeking experienced leadership to navigate dynamic markets and accelerate growth.

Management Changes

Corporate Governance

Stakeholder Impact

• **Shareholders:** The appointment of an experienced President is intended to drive commercial performance and enhance shareholder value by accelerating growth and market competitiveness.
• **Customers:** The new President's focus on accelerating execution and deepening customer relationships is expected to benefit customers through improved service and product delivery.
• **Employees:** The strengthening of the executive leadership team may provide clearer strategic direction and potentially new opportunities within the company.
• **Management:** Antony Koblish will focus solely on his CEO role, while Jeffrey Blizard will lead the company's operational and commercial efforts as President, creating a more specialized leadership structure.

Next Steps

• The full text of the Blizard Employment Agreement will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025.

Key Dates

Keywords

TELA Bio, Jeffrey Blizard, President appointment, medical technology, soft-tissue reconstruction, executive leadership, Abiomed, Medtronic, Intuitive Surgical, Boston Scientific, corporate governance, SEC filing, Form 8-K